细胞毒性T细胞
癌症研究
CD28
T细胞
免疫学
抗原
免疫系统
抗体
生物
免疫疗法
肿瘤微环境
获得性免疫系统
抗原提呈细胞
癌症免疫疗法
细胞毒性
医学
免疫
嵌合抗原受体
树突状细胞
白细胞介素21
多克隆抗体
作者
Dylan Kwart,Qiaozhi Wei,Wei‐Yi Cheng,Kamilah Ryan,Allen Y. Leary,Jacquelynn Golubov,Ciara Torres,Patrick Poon,Jacqueline J. Warsaw,Jacob Lowy,Erica Ullman,Aynur Hermann,Jennifer Finney,Lauric Haber,Albert Canturri,Dharani K. Ajithdoss,Andria Skinner,Eric Smith,Christopher Daly,Jeremy S. Rabinowitz
标识
DOI:10.1038/s41467-026-79192-3
摘要
Cytotoxic therapies such as chemotherapy and antibody-drug conjugates (ADCs) kill tumor cells directly but are limited by resistance, dose-limiting toxicity, and failure to induce durable antitumor immunity. Here we show that tumor-associated antigen (TAA)-targeted CD28 bispecific antibodies (TAAxCD28) convert cytotoxic agents into drivers of durable antitumor immunity. In humanized mouse models, combining the HER2-directed ADC trastuzumab deruxtecan (Tras-DXd) with TAAxCD28 antibodies enhances tumor rejection and promotes durable immune memory in Tras-DXd-resistant cancers, and comparable synergy is observed with 5-fluorouracil (5-FU). This therapeutic strategy allows lower or less frequent cytotoxic drug dosing, potentially limiting systemic toxicity. Mechanistically, TAAxCD28 antibodies promote the activation and expansion of clonally-restricted tumor CD8+ T cells, and adding ADCs or chemotherapy sustains this activation while preserving a naïve/stem-like pool of tumor-specific CD8+ T cells with a diversified T cell receptor repertoire. Each cytotoxic agent supports this T cell activity through a separate innate mechanism: Tras-DXd expands and activates conventional dendritic cells, whereas 5-FU reprograms suppressive myeloid cells toward an immunostimulatory phenotype. Together, these findings support pairing cytotoxic agents with TAAxCD28 bispecifics to overcome resistance and improve long-term tumor control in refractory cancers. TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated antigen (TAA) expressed on tumor cells. Here, the authors show that cytotoxic therapies reprogram the tumor microenvironment and augment the antitumor immunity induced by TAA×CD28 bispecifics.
科研通智能强力驱动
Strongly Powered by AbleSci AI